Aktienanalyse zu Travere Therapeutics Inc (TVTX)TVTXTravere Therapeutics Inc

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Travere Therapeutics Inc is currently a hold. The stock is priced at $49.60, which is significantly below the average analyst price target of $78 to $89, indicating potential upside. However, the RSI is at a low 19.437, suggesting the stock is oversold, which could lead to further price declines in the short term. The company reported a net loss of $34.79 million for Q2 2026, which is concerning, but it did achieve a revenue growth of 48% year-over-year, reaching $169 million. The main risk is the high debt to equity ratio of 2458.12%, indicating potential financial instability.